Pigmented Medulloepithelioma of the Ciliary Body

Total Page:16

File Type:pdf, Size:1020Kb

Pigmented Medulloepithelioma of the Ciliary Body CLINICOPATHOLOGIC REPORTS, CASE REPORTS, AND SMALL CASE SERIES SECTION EDITOR: W. RICHARD GREEN, MD lomata acuminata. While receiving flamed fibrovascular cores Conjunctival Papillomas highly active antiretroviral therapy (Figure 2). Nucleated keratino- Caused by Human (HAART), including indinavir sul- cytes from the paraffin-embedded Papillomavirus Type 33 fate, nevirapine, and combivir, he has specimen were microdissected un- had no new opportunistic infections der direct visualization. After protein- Conjunctival papillomas are associ- and his CD4+ cell count has in- ase K digestion, DNA sequences for ated with human papillomavirus creased above 200/mm3. He sought HPV genotypes 16, 18, and 33 were (HPV) infection. In children, the le- ophthalmic care because of occa- amplified with a kit (PCR Human sions are typically manifestations of sional bleeding from the conjuncti- Papillomavirus Detection Kit; Pan an infection acquired during deliv- val lesions. An initial ocular exami- Vera, Madison, Wis) and transblot- ery.1 In adults, conjunctival papillo- nation revealed bilateral inferior ted for Southern blot hybridization. mas are most likely venereal and are palpebral conjunctival papillomas that Briefly, the common sense primer for often associated with anogenital le- were excised from the right eye. The HPV types 16, 18, and 33 was 5Ј- sions.2 Papillomas due to HPV more results of a histopathologic examina- AAGGGCGTAACCGAAATC- frequently progress to malignancy in tion showed conjunctival papillo- GGT-3Ј and the antisense primers of patients with the human immuno- mas without atypia. The results of an each HPV strain were as follows: 5Ј- deficiency virus (HIV) infection.3 Hu- immunohistochemistry test for HPV GTTTGCAGCTCTGTGCATA-3Ј for man papillomavirus types 6, 11, 16, types 6, 11, 16, 18, 31, and 33 was HPV 16, 5Ј-GTGTTCAGTTCCGT- and 18 have been identified in be- negative. The conjunctival lesions re- GCACA-3Ј for HPV 18, and 5Ј- nign and malignant conjunctival le- curred, and he was referred to the Na- GTCTCCAATGCTTGGCACA-3Ј for sions using various antigen and DNA tional Eye Institute, Bethesda, Md. HPV 33. The hybridization probes detection techniques.2 For the first The results of our examination were were 5Ј-CATTTTATGCAC- time, to our knowledge, we report the unremarkable, except for the pres- CAAAAGAGAACTGCAATG-3Ј for finding of HPV type 33 in conjunc- ence of 1.2- to 1.5-mm nodular le- HPV 16, 5Ј-TGAGAAACACACCA- tival papillomas excised from an HIV- sions on the right upper and lower CAATACTATGGCGCGC-3Ј for positive patient. palpebral conjunctiva and large, con- HPV 18, and 5Ј-CATTTTGCAG- fluent, verrucous lesions involving the TAAGGTACTGCACGACTATG-3Ј Report of a Case. A 34-year-old HIV- left upper and lower palpebral con- for HPV 33. The polymerase chain re- positive man complained of bilateral junctiva (Figure 1). A left palpe- action was performed for each HPV conjunctival lesions of 4 years’ dura- bral conjunctival excisional biopsy strain under the following condi- tion. Ten years earlier, he was diag- was performed. A histopathologic ex- tions: 94° for 30 seconds to denature nosed as having HIV after develop- amination of the biopsy specimen re- the primers, 55° for 2 minutes for ing pneumocystis pneumonia, a vealed papillary fronds of acanthotic primer annealing, and 72° for 2 min- Mycobacterium avium-intracellulare squamous epithelium without atypia utes for primer extension. The reac- infection, and perianal HPV condy- and koilocytic changes overlying in- tion was repeated for 35 cycles, con- Figure 1. Diffuse left lower palpebral conjunctival papillomas. Figure 2. Photomicrograph showing multiple papillary fronds of acanthotic conjunctival epithelium without atypia or koilocytic changes overlying fibrovascular cores infiltrated by subacute inflammatory cells (arrow) (hematoxylin-eosin, original magnification ϫ400). (REPRINTED) ARCH OPHTHALMOL / VOL 120, FEB 2002 WWW.ARCHOPHTHALMOL.COM 202 ©2002 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 cluding with a final extension at 72° for 10 minutes. The results demon- strated HPV type 33 DNA sequences in the epithelium of the conjunctival Case papillomas (Figure 3). Postopera- tively, the patient was unavailable for follow-up. Comment. Human papillomavirus is Positive an oncogenic double-stranded DNA Control papovavirus that infects keratino- cytes and causes benign and malig- nant hyperproliferative squamous 12 3 epithelial tumors. With approxi- mately 100 subtypes identified, HPV Figure 3. Southern blot detection of amplified DNA polymerase chain reaction products for human is now the most common sexually papillomavirus (HPV) types 16, 18, and 33 from the epithelia microdissected from the conjunctival papillomas. Lane 1 indicates HPV type 16; lane 2, HPV type 18; and lane 3, HPV type 33. transmitted disease. Human papillo- mavirus is the cause of verrucae (skin warts), condylomata acuminata (ve- cently HPV type 33 has been asso- fections on the risk of ocular neo- nereal or genital warts), and muco- ciated with breast cancer in Chi- plasia. We report for the first time, cutaneous papillomas, which repre- nese and Japanese patients.9 to our knowledge, the presence of sent 7% to 12% of all conjunctival Infection with HIV increases the HPV type 33 in conjunctival papil- lesions.1,4 Most commonly associ- risk for HPV-associated malignancy lomas. Although the conjunctival ated with benign anogenital lesions and may be a cofactor linking HPV papillomas in our patient were be- and respiratory papillomas, HPV infection and neoplasia.5 The immu- nign, we suspect that the coinci- types 6 and 11 are classified as low- nodeficiency secondary to HIV may dence of the HIV infection and the risk subtypes because they rarely facilitate the oncogenic effects of oncogenic HPV type 33 places the progress to invasive cancer. Human HPV by altering the host susceptibil- patient at an increased risk for re- papillomavirus types 16 and 18 are ity to HPV infection and impairing current and persistent conjunctival considered high risk because they are immune tumor surveillance. A di- papillomas and a conjunctival ma- associated with epithelial dysplasia rect molecular interaction between lignancy. Further follow-up is and squamous cell carcinomas, par- HIV and HPV could also promote needed to determine if HAART will ticularly in the uterine cervix and anal the development of cancer. Re- ameliorate or potentiate the pa- canal. Human papillomavirus types cently, it has been shown that the tient’s risk of ocular disease. 31, 33, 35, 45, 51, 52, and 56 have HIV-1 tat protein potentiates the ex- an intermediate risk of malig- pression of HPV oncoproteins.5 Ronald R. Buggage, MD nancy.5 The effect of HAART in HIV- Janine A. Smith, MD Conjunctival HPV infection infected patients with HPV disease Defen Shen, PhD may be established during delivery is unclear. Heard and coworkers10 at- Chi-Chao Chan, MD through an infected birth canal, by tributed the reduced prevalence of Bethesda, Md sexual contact, or by autoinocula- cervical HPV lesions in HIV- tion. Human papillomavirus anti- positive women treated with HAART + Corresponding author and reprints: Dr gens are reported in 5% to 45% of to their increased CD4 cell count. Buggage, National Eye Institute, Na- conjunctival papillomas, with HPV Similarly, anal HPV lesions were tional Institutes of Health, 10 Center Dr, types 6 and 11 most commonly more likely to regress in HIV- + Bldg 10, Room 10N112, Bethesda, MD found in papillomas from children positive men with higher CD4 cell 20892-1857 (e-mail: BuggageR@intra and HPV types 16 and 18 more fre- counts who were receiving HAART. .nei.nih.gov). quently associated with dysplasia Other studies5 involving HIV- and carcinoma in older patients. positive men with anal HPV lesions 1. McDonnell PJ, McDonnell JM, Kessis T, et al. Detection of human papillomavirus type 6/11 Normal conjunctiva has also been who were receiving HAART, how- DNA in conjunctival papillomas by in situ hy- 2,6 shown to harbor HPV antigens. ever, suggest that anal HPV does not bridization with radioactive probes. Hum Pathol. Human papillomavirus type 33 regress and that the improved sur- 1987;18:1115-1119. 2. Miller DM, Brodell RT, Levine MR. The conjunc- is an uncommon genotype found in vival from HAART may paradoxi- tival wart: report of a case and review of treat- benign, dysplastic, and malignant le- cally cause an increased risk of anal mentoptions.OphthalmicSurg.1994;25:545-548. sions. In a study7 defining the dis- cancer. 3. Waddell KM, Lewallen S, Lucas SB, et al. Car- cinoma of the conjunctiva and HIV infection tribution of HPV genotypes in male An increased incidence of con- in Uganda and Malawi. Br J Ophthalmol. 1996; genital lesions, it was detected in junctival malignancy in Africa has 80:503-508. 4. Cotran RS, Kumar N, Collins T. Neoplasia: Rob- only 1 (0.6%) of 175 specimens. Se- been attributed to the combination bins Pathologic Basis of Disease. Philadelphia, Pa: ropositivity to HPV type 33 in- of HIV-induced immunosuppres- WB Saunders Co; 1999:311-312, 1048-1051. creased with age in a study8 of east- sion, HPV infection, and UV light ex- 5. Palefsyk JM. Anal squamous intraepithelial le- 3 sions in human immunodeficiency virus– ern European women. Primarily posure. This finding supports the positive men and women. Semin Oncol. 2000; found in anogenital lesions, re- combined effect of HIV and HPV in- 27:471-479. (REPRINTED) ARCH OPHTHALMOL / VOL 120, FEB 2002 WWW.ARCHOPHTHALMOL.COM 203 ©2002 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 6. Naghasfar Z, McDonnell PJ, McDonnell JM, et al. Genital tract papillomavirus type 6 in re- current conjunctival papilloma. Arch Ophthal- mol. 1986;104:1814-1815. 7. Grce M, Husnjak K, Skerlev M, Lipozencic J, Pavelic K. Detection and typing of human pap- illomaviruses by means of polymerase chain re- action and fragment length polymorphism in male genital lesions.
Recommended publications
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • What Are Brain and Spinal Cord Tumors in Children? ● Types of Brain and Spinal Cord Tumors in Children
    cancer.org | 1.800.227.2345 About Brain and Spinal Cord Tumors in Children Overview and Types If your child has just been diagnosed with brain or spinal cord tumors or you are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Brain and Spinal Cord Tumors in Children? ● Types of Brain and Spinal Cord Tumors in Children Research and Statistics See the latest estimates for new cases of brain and spinal cord tumors in children in the US and what research is currently being done. ● Key Statistics for Brain and Spinal Cord Tumors in Children ● What’s New in Research for Childhood Brain and Spinal Cord Tumors? What Are Brain and Spinal Cord Tumors in Children? Brain and spinal cord tumors are masses of abnormal cells in the brain or spinal cord 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 that have grown out of control. Are brain and spinal cord tumors cancer? In most other parts of the body, there's an important difference between benign (non- cancerous) tumors and malignant tumors (cancers1). Benign tumors do not invade nearby tissues or spread to distant areas, and are almost never life threatening in other parts of the body. Malignant tumors (cancers) are so dangerous mainly because they can spread throughout the body. Brain tumors rarely spread to other parts of the body, though many of them are considered malignant because they can spread through the brain and spinal cord tissue. But even so-called benign tumors can press on and destroy normal brain tissue as they grow, which can lead to serious or sometimes even life-threatening damage.
    [Show full text]
  • Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma Or Ependymoma (Sjyc07)
    SJCRH SJYC07 CTG# - NCT00602667 Initial version, dated: 7/25/2007, Resubmitted to CPSRMC 9/24/2007 and 10/6/2007 (IRB Approved: 11/09/2007) Activation Date: 11/27/2007 Amendment 1.0 dated January 23, 2008, submitted to CPSRMC: January 23, 2008, IRB Approval: March 10, 2008 Amendment 2.0 dated April 16, 2008, submitted to CPSRMC: April 16, 2008, (IRB Approval: May 13, 2008) Revision 2.1 dated April 29, 2009 (IRB Approved: April 30, 2009 ) Amendment 3.0 dated June 22, 2009, submitted to CPSRMC: June 22, 2009 (IRB Approved: July 14, 2009) Activated: August 11, 2009 Amendment 4.0 dated March 01, 2010 (IRB Approved: April 20, 2010) Activated: May 3, 2010 Amendment 5.0 dated July 19, 2010 (IRB Approved: Sept 17, 2010) Activated: September 24, 2010 Amendment 6.0 dated August 27, 2012 (IRB approved: September 24, 2012) Activated: October 18, 2012 Amendment 7.0 dated February 22, 2013 (IRB approved: March 13, 2013) Activated: April 4, 2013 Amendment 8.0 dated March 20, 2014. Resubmitted to IRB May 20, 2014 (IRB approved: May 22, 2014) Activated: May 30, 2014 Amendment 9.0 dated August 26, 2014. (IRB approved: October 14, 2014) Activated: November 4, 2014 Un-numbered revision dated March 22, 2018. (IRB approved: March 27, 2018) Un-numbered revision dated October 22, 2018 (IRB approved: 10-24-2018) RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH EMBRYONAL BRAIN TUMORS, HIGH-GRADE GLIOMA, CHOROID PLEXUS CARCINOMA OR EPENDYMOMA (SJYC07) Principal Investigator Amar Gajjar, M.D. Division of Neuro-Oncology Department of Oncology Section Coordinators David Ellison, M.D., Ph.D.
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Cerebral Medulloepithelioma with Long Survival —Case Report—
    p428 p.1 [100%] Neurol Med Chir (Tokyo) 47, 428¿433, 2007 Cerebral Medulloepithelioma With Long Survival —Case Report— Masato MATSUMOTO,KazuomiHORIUCHI,TakuSATO, Masahiro OINUMA, Jun SAKUMA,KyouichiSUZUKI,TatsuyaSASAKI,NamioKODAMA, Kazuo WATANABE*, and Toshimitsu SUZUKI* Departments of Neurosurgery and *Pathology, Fukushima Medical University, Fukushima, Fukushima Abstract An 8-year-old boy presented with a rare cerebral medulloepithelioma manifesting as headache, nausea, and vomiting. Neuroimaging demonstrated a mass containing a cyst in the left frontal lobe. Gross total resection of the tumor with a 1-cm margin was performed under intraoperative monitoring. The histological diagnosis was medulloepithelioma. Stereotactic radiotherapy (total dose 20 Gy) was given to the brain up to 1 cm from the surgical margin. Follow-up neuroimaging 5 years later showed no signs of recurrence. He now attends junior high school, with normal mental and physiological development. Medulloepitheliomas are rare, highly malignant embryonal tumors of the central nervous system. Combined gross total tumor resection and radiotherapy are recommended to obtain the most favorable outcome. Key words: medulloepithelioma, cerebrum, prognosis, surgery, radiation Introduction Case Report Medulloepitheliomas, first described by Bailey and An 8-year-old boy was admitted to our hospital Cushing in 1926,2) are rare, highly malignant primi- because of headache, nausea, and vomiting in tive neuroectodermal tumors usually occurring in March 2000. Neurological examination on
    [Show full text]
  • OVERVIEW of POSTER QUICK PITCHES (QP) Short Oral Poster Presentations (Max 3 Min Each) Followed by Discussion Time at the End
    (draft release date 20 May 2021) OVERVIEW OF POSTER QUICK PITCHES (QP) Short oral poster presentations (max 3 min each) followed by discussion time at the end. Time: Daily from 12:00-13:00 hrs | Format: Zoom webinars Monday 31 May: QP 1-4 Tuesday 1 June: QP 5-9 Wednesday 2 June: QP 10-14 Thursday 3 June: QP 15-18 Monday 31 May Quick Pitch 1. Gliomas Chairs: Pieter Wesseling, Signe Regner Michaelsen QP 1.1 P088. Unexpected presentation of an IDH-mutant glioblastoma at Cheryl Coulter autopsy QP 1.2 P089. PAX2 immunoexpression in adult glioblastoma Montserrat Arumí-Uría QP 1.3 P090. The evaluation of palisading necrosis, vascular endothelial Neşe Yeldir proliferation morphology using digital pathology systems and their relations with prognosis QP 1.4 P107. Prognostic role of the proliferation marker Ki-67 in glioblastomas Rikke Hedegaard Dahlrot taking tumor microenvironment, MGMT promoter methylation and post-surgical treatment into account QP 1.5 P109. Stem cell marker ALDH1A3 is not involved in mediating Julian Allgeier radiochemoresistance while RSL-3 induces ferroptotic cell death in C6 glioma model QP 1.6 P110. Differential expression of genes modulating RNA-methylation in Simon Deacon low- and high-grade glioma QP 1.7 P112. The role of aldehyde dehydrogenase 1 (ALDH1) in the treatment of Alicia Gantzkow glioma cells with cold atmospheric plasma (CAP) QP 1.8 P113. Prognostic impact of CDKN2A/B genes deletion and MGMT Maria Fernanda Ruiz promoter gene deletion on diffuse astrocytic tumors QP 1.9 P114. Utility of the new molecular platforms in the study of complex Miguel Idoate pediatric brain tumors QP 1.10 P116.
    [Show full text]
  • WHO Classification of Tumors of the Central Nervous System
    Appendix A: WHO Classification of Tumors of the Central Nervous System WHO Classification 1979 • Ganglioneuroblastoma • Anaplastic [malignant] gangliocytoma and Zülch KJ (1979) Histological typing of tumours ganglioglioma of the central nervous system. 1st ed. World • Neuroblastoma Health Organization, Geneva • Poorly differentiated and embryonal tumours • Glioblastoma Tumours of Neuroepithelial tissue –– Variants: • Astrocytic tumours –– Glioblastoma with sarcomatous compo- • Astrocytoma nent [mixed glioblastoma and sarcoma] –– fibrillary –– Giant cell glioblastoma –– protoplasmic • Medulloblastoma –– gemistocytic –– Variants: • Pilocytic astrocytoma –– desmoplastic medulloblastoma • Subependymal giant cell astrocytoma [ven- –– medullomyoblastoma tricular tumour of tuberous sclerosis] • Medulloepithelioma • Astroblastoma • Primitive polar spongioblastoma • Anaplastic [malignant] astrocytoma • Gliomatosis cerebri • Oligodendroglial tumours • Oligodendroglioma Tumours of nerve sheath cells • Mixed-oligo-astrocytoma • Neurilemmoma [Schwannoma, neurinoma] • Anaplastic [malignant] oligodendroglioma • Anaplastic [malignant] neurilemmoma [schwan- • Ependymal and choroid plexus tumours noma, neurinoma] • Ependymoma • Neurofibroma –– Myxopapillary • Anaplastic [malignant]neurofibroma [neurofi- –– Papillary brosarcoma, neurogenic sarcoma] –– Subependymoma • Anaplastic [malignant] ependymoma Tumours of meningeal and related tissues • Choroid plexus papilloma • Meningioma • Anaplastic [malignant] choroid plexus papil- –– meningotheliomatous [endotheliomatous,
    [Show full text]
  • Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— an Update
    Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— An Update Program Directors Patricia Chévez-Barrios MD and Dan S Gombos MD In conjunction with the American Association of Ophthalmic Oncologists and Pathologists McCormick Place Chicago, Illinois Saturday, Oct. 27, 2018 Presented by: The American Academy of Ophthalmology 2018 Ocular Oncology and Pathology Subspecialty Day Advisory Committee Staff Planning Group Daniel S Durrie MD Melanie R Rafaty CMP DES, Director, Patricia Chévez-Barrios MD Associate Secretary Scientific Meetings Program Director Julia A Haller MD Ann L’Estrange, Subspecialty Day Manager Dan S Gombos MD Michael S Lee MD Carolyn Little, Presenter Coordinator Program Director Francis S Mah MD Debra Rosencrance CMP CAE, Vice R Michael Siatkowski MD President, Meetings & Exhibits Former Program Directors Kuldev Singh MD MPH Patricia Heinicke Jr, Copy Editor 2016 Carol L Shields MD Mark Ong, Designer Maria M Aaron MD Gina Comaduran, Cover Designer Patricia Chévez-Barrios MD Secretary for Annual Meeting 2014 Hans E Grossniklaus MD Arun D Singh MD ©2018 American Academy of Ophthalmology. All rights reserved. No portion may be reproduced without express written consent of the American Academy of Ophthalmology. ii Planning Group 2018 Subspecialty Day | Ocular Oncology & Pathology 2018 Ocular Oncology and Pathology Planning Group On behalf of the American Academy of Ophthalmology and the American Association of Ophthalmic Oncologists and Pathologists, it is our pleasure to welcome you to Chicago and
    [Show full text]
  • MP/H Rules Presentation
    Malignant Meninges, Brain, Spinal Cord, Cranial Nerves, Pituitary Gland, Craniopharyngeal Duct and Pineal Gland 1 Equivalent Terms, Definitions, Charts and Illustrations • Benign and borderline intracranial and CNS tumors have a separate set of rules. 2 Equivalent Terms, Definitions, Charts and Illustrations • PNET (Primitive neuroectodermal tumor) – Central PNET – Supratentorial PNET • pPNET –not brain primary 3 Chart 1 Neuroepithelial Brain CNS • WHO Classification of Tumors of the brain and central nervous system • Not complete listing 4 Chart Instructions: Use this chart to code histology. The tree is arranged Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Embryonal Ependymal Pineal Choroid plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Ependymoma, Pineoblastoma Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) (9390) (9505 Olfactory neurocytoma Oligodendroglioma Ganglioglioma, malignant (9521) anaplastic (9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Atypical Ependymoblastoma Medulloepithelioma Medulloblastoma Supratentorial primitive tetratoid/rhabdoid (9392) (9501) (9470) neuroectodermal tumor tumor (9508) (PNET) (9473) Teratoid Demoplastic (9471)
    [Show full text]
  • Luth): a 15 Year Review
    REVIEW OF MANAGEMENT OF ORBITO-OCULAR MALIGNANCIES IN LAGOS UNIVERSITY TEACHING HOSPITAL (LUTH): A 15 YEAR REVIEW BY DR. ADEWUMI OLABIMPE ALABI (MBBS, IBADAN) AF/012/11/002/554 A PART II DISSERTATION SUBMITTED IN PARTIAL FULFILMENT OF THE AWARD OF FELLOWSHIP IN RADIOTHERAPY, FACULTY OF RADIOLOGY, NATIONAL POSTGRADUATE MEDICAL COLLEGE OF NIGERIA. NOVEMBER, 2015 1 DECLARATION I declare that this study titled “REVIEW OF MANAGEMENT OF ORBITO- OCULAR MALIGNANCIES IN LAGOS UNIVERSITY TEACHING HOSPITAL (LUTH): A 15 YEAR REVIEW” was carried out by me and to the best of my knowledge contains no material previously published or written by another person, nor material which has been submitted or accepted for the award of any degree or Fellowship except where due acknowledgement has been made in the text. _______________________________ DR. ADEWUMI OLABIMPE ALABI (MBBS, IBADAN) 2 CERTIFICATION This is to certify that this research project “REVIEW OF MANAGEMENT OF ORBITO- OCULAR MALIGNANCIES IN LAGOS UNIVERSITY TEACHING HOSPITAL (LUTH) : A 15 YEAR REVIEW” was conducted in the Departments of Radiotherapy and Ophthalmology (Guinness Eye Centre), LUTH, Idi-araba, Lagos and Supervised by: Professor A. T. Ajekigbe Head, Department of Radiotherapy/Consultant Clinical & Radiation oncologist, Lagos University Teaching Hospital, Idi-araba, Lagos. Signature/Date: _____________________ Professor (Mrs) F. B. Akinsola Head, 3 Department of Ophthalmology/Consultant Ophthalmologist, Guinness Eye Centre, Lagos University Teaching Hospital, Idi-araba, Lagos. Signature/Date: _____________________ Department of Radiotherapy, Lagos University Teaching Hospital, Idi – araba, Lagos state. 2nd of August, 2015. This is to certify that this research project “REVIEW OF MANAGEMENT OF ORBITO- OCULAR MALIGNANCIES IN LAGOS UNIVERSITY TEACHING HOSPITAL (LUTH) : A 15 YEAR REVIEW” by Dr Alabi, Adewumi Olabimpe of the Department Of Radiotherapy, LUTH was conducted in the Departments of Radiotherapy and Ophthalmology (Guinness Eye Centre), LUTH, Idi-araba, Lagos State.
    [Show full text]
  • Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors
    The American Journal of Pathology, Vol. 188, No. 6, June 2018 ajp.amjpathol.org ANIMAL MODELS Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors Morgan L. Shannon,* Ryann M. Fame,* Kevin F. Chau,*z Neil Dani,* Monica L. Calicchio,* Gwenaelle S. Géléoc,x{ Hart G.W. Lidov,* Sanda Alexandrescu,* and Maria K. Lehtinen*z From the Departments of Pathology* and Otolaryngologyx and the F.M. Kirby Center for Neurobiology,{ Boston Children’s Hospital, Boston; and the Program in Biological and Biomedical Sciences,z Harvard Medical School, Boston, Massachusetts Accepted for publication February 20, 2018. Choroid plexus tumors and ciliary body medulloepithelioma are predominantly pediatric neoplasms. Progress in understanding the pathogenesis of these tumors has been hindered by their rarity and lack Address correspondence to fi Maria K. Lehtinen, Ph.D., of models that faithfully recapitulate the disease. Here, we nd that endogenous Myc proto-oncogene Department of Pathology, Boston protein is down-regulated in the forebrain neuroepithelium, whose neural plate border domains give Children’s Hospital, 300 Long- rise to the anterior choroid plexus and ciliary body. To uncover the consequences of persistent Myc wood Ave., Boston, MA 02115. expression, MYC expression was forced in multipotent neural precursors (nestin-Cre:Myc), which E-mail: maria.lehtinen@ produced fully penetrant models of choroid plexus carcinoma and ciliary body medulloepithelioma. childrens.harvard.edu. Nestin-mediated MYC expression in the epithelial cells of choroid plexus leads to the regionalized formation of choroid plexus carcinoma in the posterior domain of the lateral ventricle choroid plexus and the fourth ventricle choroid plexus that is accompanied by loss of multiple cilia, up-regulation of protein biosynthetic machinery, and hydrocephalus.
    [Show full text]